775526-39-1

Upstream product

• 1018500-99-6 C₁₅H₁₂N₂O₂ 
• 619-05-6 3,4-diaminobenzoic acid 
• 104-87-0 4-methyl-benzaldehyde 
• 41468-10-4 α-hydroxy-α-toluenesulfonate 

Downstream Products

• 1259500-79-2 4''-O-(2-(4-methylphenyl)-1H-benzimidazole-5-carbonyl)hydrazinecarbonylclarithromycin 
• 1455436-55-1 4-methylbenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-56-2 4-methoxybenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-57-3 4-bromobenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-58-4 4-chlorobenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-59-5 4-fluorobenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-60-8 4-nitrobenzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-61-9 4-carboxybenzaldeyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 
• 1455436-54-0 benzaldehyde N-[1H-benzimidazol-2-(4-methylphenyl)5⁽⁶⁾-yl]hydrazone 

Relevant academic research and scientific papers

Synthesis and antimicrobial evaluation of some 2,5-disubstituted benzimidazole derivatives

Some benzimidazole derivatives bearing hydrazone moiety were synthesized and their in vitro antimicrobial activity was determined against various gram-positive and gram-negative bacteria, and fungi using microbroth dilution method. The structures of all n

Novel clarithromycin analogs with C-4′′ 2-arylbenzimidazolyl bishydrazide side chain: Synthesis and antibacterial evaluation

A series of novel 4′′-O-2-arylbenzimidazolyl derivatives of clarithromycin were synthesized and evaluated. These 4′′-O-2- arylbenzimidazolyl derivatives demonstrated excellent activity against erythromycin-susceptible strains and showed remarkably improved activity against erythromycin-resistant strains compared with the references. In particular, compound 7c, which possesses the terminal 2-(2-methoxyphenyl)benzimidazolyl group on the C-4′′ bishydrazide side chain, not only presented the most potent activity against erythromycin-susceptible Streptococcus pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923, exhibiting 4-fold and 4-fold higher efficacy than the parent clarithromycin, but also displayed the highest activity against erythromycin-resistant Streptococcus pneumoniae expressing the mef gene and the erm gene, which was 133-fold and 32-fold better than clarithromycin or azithromycin, respectively.

Synthesis and antibacterial activity of novel 4″-O-benzimidazolyl clarithromycin derivatives

Novel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. These benzimidazolyl derivatives exhibited excellent activity against erythromycin-susceptible strains better than the references, and some of them showed greatly improved activity against erythromycin-resistant strains. Compounds 16 and 17, which have the terminal 2-(4-methylphenyl)benzimidazolyl and 2-(2-methoxyphenyl)benzimidazolyl groups on the C-4″ bishydrazide side chains, were the most active against erythromycin-resistant Staphylococcus pneumoniae expressing the erm gene and the mef gene. In addition, compound 17 exhibited the highest activity against erythromycin-susceptible S. pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923 as well. It is worth noting that the 4″-O-(2-aryl)benzimidazolyl derivatives show higher activity against erythromycin-susceptible and erythromycin-resistant strains than the 4″-O-(2-alkyl)benzimidazolyl derivatives.